Dr. Dwivedi holds a doctoral degree in Pharmaceutical sciences from the Central Drug Research Institute (CDRI) & Integral University Lucknow. His doctoral thesis was on elucidating the role of Nrf2 transcription factors in learning and memory impairment. During his time working with industrial drug discovery & development at Panacea Biotec Ltd (2014-2019) he was responsible for target identification, target product profiling, primary in-vivo and in-vitro Pharmacokinetics-Pharmacodynamics (PK-PD) profiling and Investigational New Drug (IND) enabling studies of  New Chemical Entities (NCEs) in therapeutic area of metabolic and neurological disorders. Previously as a Project Manager-Biologicals, he was responsible for Project Management of New Vaccine development, Technology Transfer, Drug Substance and Drug product manufacturing operations and supply chain management in the office of Chief Scientific & Operating officer. He has taught (2008-2010) Anatomy Physiology, Pathophysiology & Pharmacology to undergraduates’ at K.N.I.M.T. faculty of pharmacy, Sultanpur, Uttar Pradesh India. His overall expertise includes animal behavioral studies & molecular studies, as well as animal model of diabetes and neurological disorder such as dementia (memory impairment). He joined The Kumar Lab in May 2021, and he will contribute to preclinical testing of novel dosage forms in immuno-inflammatory disease models.

Education
2015 PhD in Pharmaceutical Sciences (Pharmacology) CSIR-C.D.R.I. & Integral University Lucknow, Uttar Pradesh India
2008 M Pharm in Pharmacology from NDMVP’s College of Pharmacy & Pune University, Pune Maharashtra, India
2006 B Pharm in Pharmaceutical Sciences from A.N.D. College of Pharmacy & UPTU Lucknow, Uttar Pradesh, India

​Email: sdwivedi1@ua.edu
Phone: 205-348-2441    

---

Publications

• Systemic anti-inflammatory therapy aided by curcumin-laden double-headed nanoparticles combined with injectable long-acting insulin in a rodent model of diabetes eye disease. R. Ganugula, M. Arora, S. Dwivedi, D. S. Chandrashekar, S. Varambally, E. M. Scott, M. N. V. Ravi Kumar.  ACS Nano 17: 6857-6874, 2023.
• Nanocurcumin combined with insulin alleviates diabetic kidney disease through P38/P53 signaling axis. R. Ganugula, N. K. Nuthalapati, S. Dwivedi, D. Zou, M. Arora, R. Friend, D. Sheikh-Hamad, R. Basu, M. N. V. Ravi Kumar.  J. Control. Release 353: 621-633, 2023.
• Oral nano-curcumin alone or in combination with insulin alleviates diabetic neuropathy in rats. S. Dwivedi, A. Gottipati, R. Ganugula, M. Arora, R. Friend, R. Osburne, A. Rodrigues-Hoffman, R. Basu, H.-L. Pan, and M. N. V. Ravi Kumar. Mol. Pharm. 19: 4612-4624, 2022. (Cover article)